A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Infliximab (Primary) ; Ustekinumab (Primary) ; Acitretin; Adalimumab; Antipsoriatics; Ciclosporin; Etanercept; Methotrexate; Psoralens
- Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- Acronyms PSOLAR
- Sponsors Janssen Biotech
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned number of patients changed from 12000 to 1013.
- 02 Dec 2016 Planned primary completion date changed from 1 Dec 2020 to 1 May 2021.